Stockrabit · Analysts
Questions across 14 calls

Prashant Nair

Ambit Capital

Acutaas Chemicals Limited

Acutaas Chemicals Limited CC-Jun25.pdf · 2025-07-30
Just have one question on your margins. So Naresh Bhai, usually, your first quarter margins are the lowest and then it keeps getting progressively better 2Q, 3Q and 4Q. So, should we expect a similar trend this year as well, especially on the pharma side? Or would this have changed now that your CDMO contract has started? So, would it be more evenly spread? How do we think about margins now?
Okay. Understood. And just one question on the Specialty Chemicals side. So how close are we or how much more time in terms of maybe quarters or say years will take to get to a steady-state margin profile there where say, peak margins in that business?

Max Healthcare Institute Limited

Max Healthcare Institute Limited CC-Mar25.pdf · 2025-05-21
Yes. Thanks. Good morning, everyone. Just had a question on the expansion plan, since there is no slide on that in this quarter's presentation. So the 1,400 -odd beds that you were planning to add in Financial Year ‘26, that remains on course, would it roughly be in the same range?
Okay. And of these, how many would you operationalize this year, if you can just give an approximate range? I imagine the bigger project s would have not all beds operational from the beginning. How do you calibrate that?
Max Healthcare Institute Limited CC-Jun24.pdf · 2024-08-02
As your new projects now start coming onstream over the next few years, if you take some of your larger brownfield projects like say in Saket or Nanavati, when the new beds come online, do they have similar case mix, payor mix, ARPOB, etc., as the older base, or would we start at slightly different levels and then match up to how the existing hospital beds does?
Second question is in th ese projects, would the investment in the beds follow a similar pattern for say a new Greenfield project where you front load everything, right? So, in brownfield beds, is there a period maybe after the first year, second year when you have to step up either investment in people or equipment for a ramp up, or are they all done at the beginning?

Natco Pharma Limited

Natco Pharma Limited CC-Dec24.pdf · 2025-02-13
Yes, thanks. So, my question was similar. I mean, on the R&D spend part, you know, I get what you mentioned. Would you be able to share what your, say, EBITDA margin was on a pre-R&D basis? Just trying to use this quarter to get some sense of how your margins could look on an ex- development basis. So, that was the objective.
So, then, yes, just one additional clarification. You mentioned earlier 8 to 10%. That's on annual revenue, right, that you mentioned that you are spending?

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. CC-Sep24.pdf · 2024-10-23
Related to how do you plan your network as you go into the future. 5-6 years back, you had a certain hub -and-spoke model with a certain ratio of collection centers to labs which has served you well so far. Now as you go into Tier-3 markets increasingly or into newer markets, would that change in any manner? So, I am talking more about number of collection centers in relation to number of labs. Would you be able to do with more collection centers relative to labs or would you need to set up more labs, how do you think about the network as you go into your next phase o f development?
Dr. Lal Path Labs Ltd. CC-Dec23.pdf · 2024-02-01
Dr. Om, I think you partially addressed this but if you could elaborate a bit more . When you talk about maybe increasing lab infra to target Tier-2, Tier-3 cities, is there any way you can quantify either number of labs, or if you could even give qualitative color on will these labs be similar to what you currently run in the bigger cities, or will they kind of have slightly more limited test menu, will the number of spokes they can support or number of connection centers they can support be higher, lower than what you have currently? I mean is the nature of the network likely to change or is it just adding the way you have been adding so far?
Is there any target in terms of setting up XX number of labs.

Apollo Hospitals Enterprise Limited

Apollo Hospitals Enterprise Limited CC-Sep24.pdf · 2024-11-07
The cost of setting up a hospital or, say, per bed cost , with that change in what a hospital looks like, increasing use of robotics, also the fact that onco is a much bigger part of almost every hospital practice now, how much would a per bed cost for a full- service hospital change over the last, say, 5-7 years, in your opinion? And do you think the price increases that you have seen are adequate or are in line with the increase in cost? Or have you been kind of recovering a lot of it through greater efficiencies? I mean, how do you see the various variables laid out on that front?
And the second question is slightly related . So, given that your hospitals are now a lot more tertiary care focused with the kind of investment you are making . Also, you recently just mentioned earlier in the call that you are seeing a lot more secondary care procedures coming your way , s o how do you balance that given that with insurance compensation going up , this may not change immediately? Do you need to look at different ways of handling that patient flow or would it not be suboptimal to have them occupy beds, which are essentially set up for tertiary care treatment. How do you balance that within the network?

Fortis Healthcare Limited

Fortis Healthcare Limited CC-Mar24.pdf · 2024-05-24
Just a couple of questions. The first question is on your current network. I mean, would you still expect some more rationalization of the network or hospitals either being sold or discontinued? Or are you largely done with that?
And from the current hospitals that you have, are there still any which are not doing as well as you want them to do and where you could look at options similar to what you did with the Chennai hospitals? Or do you think that this set of hospitals you will continue with and work on to improve them.

Eris Lifesciences Limited

Eris Lifesciences Limited CC-Sep23.pdf · 2023-11-08
My first question is the revenue number that you have provided for the acquired business from Biocon, are those revenues at company level or do we have to mark them down to get the revenues that you would approve?
Second question is, if you take your main therapy, say, Diabetes, Cardiac, Dermatology now and maybe VMN, would you have a sense of how much of these markets would you be covering now ? What is the proportion of your covered market to the overall market just to get a sense of how much more you have in terms of gaps to fill?